NCT02991651 2025-05-14
Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC
Io Therapeutics
Phase 1 Terminated
Clinical Trials
50 trialsNCT00503971 2025-03-07
Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.
Spanish Lung Cancer Group
Phase 1/2 Terminated
NCT02588261 2024-12-10
SOLAR
Astellas Pharma Inc
Phase 3 Terminated
NCT02495233 2024-11-27
A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
Astellas Pharma Inc
Phase 1/2 Terminated
NCT00750698 2023-07-06
A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib
Syndax Pharmaceuticals
Phase 2 Terminated
NCT01487174 2022-05-13
KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy
Kadmon Corporation, LLC
Phase 3 Terminated
NCT01455389 2022-03-02
TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer
Genprex, Inc.
Phase 1/2 Terminated
NCT04165031 2021-11-24
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
Eli Lilly and Company
Phase 1/2 Terminated
NCT01244191 2021-04-06
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
Daiichi Sankyo
Phase 3 Terminated
NCT02318368 2020-10-22
FOCAL
AVEO Pharmaceuticals, Inc.
Phase 2 Terminated
NCT01188707 2020-10-19
A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer
Herlev Hospital
Phase 1/2 Terminated
NCT01857271 2020-07-08
EVENT
Albert Einstein College of Medicine
Phase 2 Terminated
NCT03460678 2020-03-05
Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients.
Hikma Pharmaceuticals LLC
Phase 4 Terminated
NCT02468661 2020-02-24
A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification
Novartis
Phase 1 Terminated
NCT02117024 2020-02-05
A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
Heat Biologics
Phase 2 Terminated
NCT02770014 2019-11-22
Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01822496 2019-08-05
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT02080078 2019-05-03
A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline
AHS Cancer Control Alberta
Phase 1 Terminated
NCT02775006 2019-04-30
Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma
The Netherlands Cancer Institute
Phase 3 Terminated
NCT02556593 2019-04-12
IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases
Sun Yat-sen University
Phase 2 Terminated
NCT01115803 2019-02-05
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT00281021 2018-03-29
Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer
University of Louisville
Phase 2 Terminated
NCT00096265 2018-03-09
Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 3 Terminated
NCT02342353 2018-02-27
Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)
Washington University School of Medicine
Phase 1 Terminated
NCT02134015 2018-01-23
HER3-Lung
Daiichi Sankyo
Phase 3 Terminated
NCT00592007 2017-06-06
Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer
University of California, San Diego
Phase 2 Terminated
NCT00351039 2017-03-23
Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Terminated
NCT02095782 2017-03-03
INNOVATE
Guangdong Association of Clinical Trials
Phase 2 Terminated
NCT01026844 2017-01-30
Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC)
Massachusetts General Hospital
Phase 1 Terminated
NCT01383148 2017-01-05
TIME
Transgene
Phase 2/3 Terminated
NCT01377376 2016-12-07
ATTENTION
Kyowa Kirin Co., Ltd.
Phase 3 Terminated
NCT01515969 2016-07-12
Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)
Stanford University
Phase 1 Terminated
NCT00063258 2016-05-09
Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00738881 2015-10-29
MARVEL
National Cancer Institute (NCI)
Phase 3 Terminated
NCT02134886 2015-10-06
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
National Cancer Institute (NCI)
Phase 1 Terminated
NCT01193881 2015-09-29
RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00749567 2015-09-28
Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer
Hellenic Oncology Research Group
Phase 2 Terminated
NCT00391586 2015-08-17
Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00707252 2015-04-21
Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer
Louisiana State University Health Sciences Center Shreveport
Phase 1 Terminated
NCT00940875 2015-04-02
A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT00251589 2015-03-06
A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT00452075 2014-12-11
Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for Patients Unfit for Chemotherapy
Rigshospitalet, Denmark
Phase 2 Terminated
NCT00976677 2014-05-30
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00673049 2013-07-24
NSCLC
Pfizer
Phase 3 Terminated
NCT00773383 2013-06-24
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.
Hoffmann-La Roche
Phase 2 Terminated
NCT00087269 2013-06-06
Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00042835 2013-02-01
Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00522938 2012-06-28
Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Chroma Therapeutics
Phase 1/2 Terminated
NCT00554775 2011-12-12
TACTIC
University College, London
Phase 2 Terminated
NCT00830245 2011-07-26
A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer
Clinical Research Center for Solid Tumor, Korea
Phase 2 Terminated